AcquisitionOther
Biogen Inc. acquired Apellis Pharmaceuticals, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Biogen Inc. -> Apellis Pharmaceuticals, Inc. · $41.00 per share plus CVRs up to $4.00 per share
Adds two commercialized products EMPAVELI and SYFOVRE, significantly bolstering near-term growth outlook and expanding into nephrology
Open source record (SEC) ↗